The post was also published by nonprofit organization for aging research, Norn Group.

Read it here: www.gordian.bio/blog/gene-th...

Chase’s work is a key piece of Mosaic Screening, the phase of the Gordian Platform where we create a pooled library of hundreds of therapies and test them in vivo in individual Patient Avatars.
#GeneTherapy
#Biotech
#DrugDiscovery

Basically speaking, he’s using a spinning technique to separate and collect the small viruses delivering gene therapies without the cells they were made in, then preparing the pure sample for the next steps of the research and development process.

We used the time to celebrate everything we’ve accomplished over the past year and map out ambitious plans for clinical development of our lead therapies!

#Biotech
#TeamBonding
#InVivoResearch

But at Gordian, we believe that allowing talented and deserving researchers like Alex to contribute on the same level without having to pause their careers to go back to school will advance our mission and offer enrichment and opportunity that wouldn’t be available academically.

Traditionally, securing a scientist title usually requires a PhD.

Listen to the liveliest description of the Gordian platform yet! www.kqed.org/radio/progra...

Listen now: www.biotechnation.com/episodes/rep...

It’s exciting to hear about complex scientific topics in such a high-energy, accessible conversation. Big thanks to the always-captivating Dr. Gunn and her crew!

The latest episode dropped today, featuring co-founders Francisco LePort and Martin Borch Jensen discussing how Gordian’s high-throughput in vivo screening platform will transform drug discovery for age-related disease.

Read more here: www.gordian.bio/blog/drug-di... (🧵9/9)

Current applications of AI to drug discovery miss the forest for the trees. AI makes the existing drug discovery paradigm more efficient, but fails to correct structural flaws in the legacy discovery process. This has led to questionable success so far. (🧵8/9)

By training and screening in vivo, our predictions for in vivo results are automatically, dramatically better. This isn’t because we use better AI or more advanced assays. This is because our training data comes from the same system as our validation data. (🧵7/9)

Gordian has redesigned the preclinical process from the ground up. All drug developers must validate in animals. Gordian trains for discovery in animals from step one. Our preclinical discovery process takes place entirely in vivo. (🧵6/9)

This means drug discovery models are being trained in the wrong system. You don’t train a self-driving car on the California Vehicle Code, you train it on the road. If you’re going to test your drug in a living mammal, you must train for discovery in that living mammal. (🧵5/9)

A tell-tale sign that we haven’t taken full advantage of new tools and AI is that souped up preclinical processes look essentially the same, just with AI and robotics added. Here is Recursion’s 17 step preclinical process: bit.ly/4fwB2TF. In vivo validation doesn’t come until step 17. (🧵4/9)

AI, robotics, and new -omics have made this process much more efficient, but it is still the same fundamental discovery process. This image pulled from a quick Google search summarizes the process in 12 (not so) easy steps. In vivo validation comes in at step 12. (🧵3/9)